PMD-026

Phase 2

MOLECULAR PARTNERS AG (MOLN)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

MOLNPhase 2$148M

PMD-026 Phase 2 Est. Readout

PMD-026• Metastatic Breast Cancer61

Dec 2026~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

1 competitor in Metastatic Breast Cancer

ATNXOraxol

Phase 3

View Full Landscape

Drug Information

Target Indication

Metastatic Breast Cancer

Clinical Trial

NCT04115306

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MOLN

MOLECULAR PARTNERS AG

Biological Products, (No Diagnostic Substances)•Europe•NASDAQ

Related Pipeline

4D-150 IVT (3E10 vg/eye)Phase 3

Macular Neovascularization Secondary to Age-Related Macular Degeneration

MP0420Phase 3

COVID-19

MP0250 plus BOR+DEXPhase 2

Multiple Myeloma in Relapse

[212Pb]Pb-MP0712Phase 2

Large Cell Neuroendocrine Carcinoma

MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1Phase 2

Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts